Clinical characteristics of Chlamydia pneumoniae pneumonia in 145 children: a single-centre retrospective study
-
By
-
Yongkang Wang
-
Tianyu Huang
-
Weikang Gao
-
Yun Liu
-
Wenna Shen
-
Tingting Yang
-
Hongchuan Yu
-
Xinrong Sun
-
June 25, 2026
-
Clinical Scorecard: Clinical Features of Chlamydia pneumoniae Pneumonia in 145 Pediatric Patients: A Retrospective Analysis from a Single Centre
At a Glance
| Category | Detail |
|---|
| Condition | Chlamydia pneumoniae pneumonia |
| Key Mechanisms | Atypical pathogen spread via respiratory droplets; not susceptible to β-lactam antibiotics. |
| Target Population | Children aged 1 to 18 years. |
| Care Setting | Pediatric clinical practice. |
Key Highlights
- Cough was present in 99.3% of cases, predominantly wet cough.
- Median age at onset was 11 years with a median disease duration of 14 days.
- Fever observed in 44.8% of cases, primarily low to moderate grade.
- Unilateral lung involvement in 75.2% of cases.
- 93 children received azithromycin and 65 received doxycycline for treatment.
Guideline-Based Recommendations
Diagnosis
- Positive serum CP IgM or positive CP nucleic acid test from throat swab or bronchoalveolar lavage fluid.
Management
- Macrolides, tetracyclines, and fluoroquinolones are preferred treatment options.
Monitoring & Follow-up
- Clinical manifestations and laboratory test results should be monitored for treatment response.
Risks
- Potential for false-positive results with single serum IgM test due to cross-reactivity.
Patient & Prescribing Data
145 children diagnosed with Chlamydia pneumoniae pneumonia.
Azithromycin and doxycycline were the primary anti-infective therapies.
Clinical Best Practices
- Early recognition of characteristic manifestations can facilitate timely diagnosis.
- Consider concurrent infections with other pathogens in children with CP pneumonia.
Related Resources & Content
